推薦產品
生物源
mouse
品質等級
100
500
共軛
unconjugated
抗體表格
culture supernatant
抗體產品種類
primary antibodies
無性繁殖
11, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (415M-14)
vial of 0.5 mL concentrate (415M-15)
bottle of 1.0 mL predilute (415M-17)
vial of 1.0 mL concentrate (415M-16)
bottle of 7.0 mL predilute (415M-18)
製造商/商標名
Cell Marque™
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
同型
IgG1
控制
breast carcinoma, prostate adenocarcinoma, tonsil
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
nuclear
基因資訊
human ... EZH2(2146)
一般說明
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) in order to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer types. Hyperactivation of EZH2, either by overexpression or mutations, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma. EZH2 overexpression has been reported in non-small cell lung cancers and lymphoma.The EZH2 protein is rarely detected in normal breast duct epithelium and in normal and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas, although only in 20% (1/5) of small lymphocytic lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma have not been shown to express this protein. Recent studies also have demonstrated EZH2 is aberrantly over-expressed in pediatric rhabdomyosarcoma, independent of the histological subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations
品質
IVD | IVD | IVD | RUO |
聯結
EZH2 Positive Control Slides, Product No. 415S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
準備報告
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
未找到適合的產品?
試用我們的產品選擇工具.
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
Acta pharmacologica Sinica, 35(2), 161-174 (2013-12-24)
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those
Virchows Archiv : an international journal of pathology, 463(5), 697-711 (2013-08-21)
Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ
Nature, 419(6907), 624-629 (2002-10-11)
Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer. Although effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic prostate cancer remains essentially incurable. Here we show, through
BMC medicine, 9, 63-63 (2011-05-26)
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure.
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務